Gilead Sciences has received exclusive worldwide rights to research, develop and commercialise Boehringer Ingelheim’s novel non-catalytic site integrase inhibitors (NCINIs) for HIV.
Included in the agreement is Boehringer’s BI 224436 lead compound, which has recently been evaluated in a Phase1a dose-escalation study.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
NCINIs work by targeting the component of the virus responsible for viral DNA’s incorporation in the human genome, inhibiting HIV integrase by binding it to a novel site.
Under the terms of the agreement, Boehringer will receive an upfront payment and could also receive additional milestone payments based on development, regulatory and commercial advancements.
